2024
MULTIMORBIDITY COMBINATIONS AND DEPRESSIVE SYMPTOM TRAJECTORIES AMONG US OLDER ADULTS
Bishop N, Walker K, Nagel C, Newsom J, Botoseneanu A, Allore H, Quiñones A. MULTIMORBIDITY COMBINATIONS AND DEPRESSIVE SYMPTOM TRAJECTORIES AMONG US OLDER ADULTS. Innovation In Aging 2024, 8: 356-356. PMCID: PMC11690501, DOI: 10.1093/geroni/igae098.1161.Peer-Reviewed Original ResearchHealth and Retirement StudyMultimorbidity combinationsTrajectories of depressive symptomsDepressive symptomsOlder adultsIncreased risk of depressionPhysician-diagnosed conditionsAverage depression scoreRisk of depressionComplex sampling designIncreased patient burdenMultimorbidity patternsRetirement StudyBaseline depressive symptomatologyMultimorbidityDepression scoresPatient burdenDepressive symptomatologyIncreased riskChildhood characteristicsLatent growth trajectoriesAdultsSampling designSymptomsHeart conditionsIncremental hemodialysis transition in veterans and nonveterans with kidney failure
Rhee C, Kovesdy C, Unruh M, Crowley S, Geller D, Goldfarb D, Kraut J, Rastegar M, Rifkin I, Kalantar-Zadeh K. Incremental hemodialysis transition in veterans and nonveterans with kidney failure. Current Opinion In Nephrology & Hypertension 2024, 34: 33-40. PMID: 39611277, DOI: 10.1097/mnh.0000000000001040.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeEnd-stage kidney diseaseResidual kidney functionAssociated with impaired health-related quality of lifeImpaired health-related quality of lifeTwice-weekly hemodialysisLow patient burdenHigher mortality riskQuality of lifeRandomized controlled trialsTransition to dialysisReceive careResidual kidney function preservationIncremental hemodialysisInitiation of hemodialysis treatmentMortality riskPatient burdenESKD populationPragmatic studyYear of treatmentVeteransStandard of careThrice-weekly hemodialysisDialysis transitionCareSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regions
2023
Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities
Blauvelt A, Gondo G, Bell S, Echeverría C, Schmitt-Egenolf M, Skov L, van de Kerkhof P, Howard L, Strober B. Psoriasis Involving Special Areas is Associated with Worse Quality of Life, Depression, and Limitations in the Ability to Participate in Social Roles and Activities. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 100-106. PMID: 39296315, PMCID: PMC11361513, DOI: 10.1177/24755303231160683.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexBody surface area involvementPatient-reported outcome measuresSurface area involvementDisease-specific qualityQuality of lifeExtensive psoriasisPsoriasis severityArea involvementPatient burdenOutcome measuresSevere diseaseClinical experienceSeverity IndexPsoriasisDiseasePresent studyPatientsSeveritySecondary Ischemic Stroke Prevention
Bangad A, Abbasi M, de Havenon A. Secondary Ischemic Stroke Prevention. Neurotherapeutics 2023, 20: 721-731. PMID: 36877331, PMCID: PMC10275832, DOI: 10.1007/s13311-023-01352-w.Peer-Reviewed Original ResearchConceptsSecondary ischemic stroke preventionIschemic stroke preventionRecurrent ischemic strokeStroke preventionIschemic strokeRisk factorsMajor public health concernSecondary stroke preventionLifestyle risk factorsVascular risk factorsRecurrent stroke riskAvailability of treatmentPublic health concernHealth care systemAHA guidelinesStroke riskSurgical treatmentHealth burdenPatient burdenFirst strokeStrokeHealth concernCare systemPreventionTreatment
2022
How Much Data Is Enough? A Reliable Methodology to Examine Long-Term Wearable Data Acquisition in Gait and Postural Sway
Meyer B, Depetrillo P, Franco J, Donahue N, Fox S, O’Leary A, Loftness B, Gurchiek R, Buckley M, Solomon A, Ng S, Cheney N, Ceruolo M, McGinnis R. How Much Data Is Enough? A Reliable Methodology to Examine Long-Term Wearable Data Acquisition in Gait and Postural Sway. Sensors 2022, 22: 6982. PMID: 36146348, PMCID: PMC9503816, DOI: 10.3390/s22186982.Peer-Reviewed Original ResearchConceptsFree-living environmentBalance impairmentIntra-class correlationPostural sway measuresMeasures of gaitEvaluation of gaitWearable accelerometer dataWear durationSway measuresPostural swayCapturing gaitEstablished patientMovement variabilityImpairment measuresGaitPatient burdenAccelerometer dataClinical measuresDays of monitoringWearable sensor-based methodsSensor wearSwayRegression analysisComprehensive assessmentStudy costsHeart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies
Allen LA, Teerlink JR, Gottlieb SS, Ahmad T, Lam CSP, Psotka MA. Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies. Circulation Heart Failure 2022, 15: e008594. PMID: 35000432, DOI: 10.1161/circheartfailure.121.008594.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyMedical therapyReduced ejection fractionHealth care delivery researchAdverse eventsCardiac benefitsSerum creatinineBlood pressureEjection fractionHeart failureRoutine carePatient burdenHeart rateNew therapiesPatient harmHigh dosesPatientsPsychosocial domainsPocket costsTherapeutic opportunitiesClinical useTherapyNew drugsPhysiological domainsSpending function
2020
The Unintended Consequences of Nonoperative Management of Acute Appendicitis
Oliveira K, Jean RA, Gonsai R, Maduka RC, Gibson CE, Chiu AS, Ahuja V. The Unintended Consequences of Nonoperative Management of Acute Appendicitis. Journal Of Surgical Research 2020, 255: 436-441. PMID: 32619858, DOI: 10.1016/j.jss.2020.05.018.Peer-Reviewed Original ResearchConceptsNonoperative managementAcute appendicitisNational Readmission DatabaseOdds of readmissionCause readmission rateRisk of readmissionTraditional operative approachMultivariable linear regressionMore comorbiditiesIndex hospitalizationReadmission ratesSurgical managementAdult admissionsOperative approachPatient burdenAppendicitisPatientsSix monthsAppendectomyReadmissionSignificant increaseMost casesLinear regressionManagementComorbidities
2017
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
Bakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease. PLOS ONE 2017, 12: e0178413. PMID: 28727801, PMCID: PMC5518995, DOI: 10.1371/journal.pone.0178413.Peer-Reviewed Original ResearchConceptsSickle cell diseaseChronic blood transfusionsBone marrow transplantationDisease-modifying therapiesTreatment-related decisionsTreatment optionsCell diseasePhysician perspectivesAvailable disease-modifying therapiesLong-term adverse effectsPhysician-related factorsAvailable treatment optionsDisease-related factorsPossible treatment optionsPatients/familiesInherited blood disorderBlood transfusionMarrow transplantationPhysician interviewsPatient burdenPhysicians' perceptionsPatient's perspectivePhysicians' approachPatient engagementTreatment plan
2016
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani H, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano GM, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal Of Heart Failure 2016, 18: 482-489. PMID: 27071916, DOI: 10.1002/ejhf.516.Peer-Reviewed Original ResearchConceptsHeart failure clinical trialsComposite endpointClinical trialsNew composite endpointHeart failureHeart failure treatmentEffect of therapyHealth system perspectiveOverall treatment effectRepeat hospitalizationPlanned trialsFunctional statusFailure treatmentOutcome eventsPatient burdenEfficacy assessmentPatient experienceNew treatmentsTrialsAdverse effectsEfficiency of trialsEndpointTrial efficiencyTreatment effectsPrimary measure
2015
HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study
McCoy RG, Van Houten HK, Ross JS, Montori VM, Shah ND. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study. The BMJ 2015, 351: h6138. PMID: 26646052, PMCID: PMC4673101, DOI: 10.1136/bmj.h6138.Peer-Reviewed Original ResearchConceptsType 2 diabetesGlycemic controlControlled type 2 diabetesNational administrative claims databaseExcessive testingAdministrative claims databaseGood glycemic controlStable glycemic controlStudy patientsTreatment intensificationSevere hypoglycemiaTreatment regimenStudy cohortUS patientsClaims databasePotential overtreatmentUS cohortHypoglycemic drugsInsulin treatmentPatient burdenRetrospective analysisStudy populationUS adultsDiabetes managementObservational population
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply